Literature DB >> 26511098

Acute Hepatitis E Virus infection with coincident reactivation of Epstein-Barr virus infection in an immunosuppressed patient with rheumatoid arthritis: a case report.

Detlev Schultze1, Bernhard Mani2, Günter Dollenmaier3, Roland Sahli4, Andrea Zbinden5, Pierre Alexandre Krayenbühl6.   

Abstract

BACKGROUND: Hepatitis E virus (HEV) is the most recently discovered of the hepatotropic viruses, and is considered an emerging pathogen in developed countries with the possibility of fulminant hepatitis in immunocompromised patients. Especially in the latter elevated transaminases should be taken as a clue to consider HEV infection, as it can be treated by discontinuation of immunosuppression and/or ribavirin therapy. To our best knowledge, this is a unique case of autochthonous HEV infection with coincident reactivation of Epstein-Barr virus (EBV) infection in an immunosuppressed patient with rheumatoid arthritis (RA). CASE
PRESENTATION: A 68-year-old Swiss woman with RA developed hepatitis initially diagnosed as methotrexate-induced liver injury, but later diagnosed as autochthonous HEV infection accompanied by reactivation of her latent EBV infection. She showed confounding serological results pointing to three hepatotropic viruses (HEV, Hepatitis B virus (HBV) and EBV) that could be resolved by detection of HEV and EBV viraemia. The patient recovered by temporary discontinuation of immunosuppressive therapy.
CONCLUSIONS: In immunosuppressed patients with RA and signs of liver injury, HEV infection should be considered, as infection can be treated by discontinuation of immunosuppression. Although anti-HEV-IgM antibody assays can be used as first line virological tools, nucleic acid amplification tests (NAAT) for detection of HEV RNA are recommended--as in our case--if confounding serological results from other hepatotropic viruses are obtained. After discontinuation of immunosuppressive therapy, our patient recovered from both HEV infection and reactivation of latent EBV infection without sequelae.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26511098      PMCID: PMC4625942          DOI: 10.1186/s12879-015-1146-y

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  20 in total

Review 1.  Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease.

Authors:  Hiroshi Kimura; Yoshinori Ito; Ritsuro Suzuki; Yukihiro Nishiyama
Journal:  Rev Med Virol       Date:  2008 Sep-Oct       Impact factor: 6.989

2.  Serological cross reactivity to CMV and EBV causes problems in the diagnosis of acute hepatitis E virus infection.

Authors:  Catherine Hyams; Diana A Mabayoje; Ruth Copping; Desmond Maranao; Mauli Patel; Wendy Labbett; Tanzina Haque; Daniel P Webster
Journal:  J Med Virol       Date:  2013-11-08       Impact factor: 2.327

3.  ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.

Authors:  Naga P Chalasani; Paul H Hayashi; Herbert L Bonkovsky; Victor J Navarro; William M Lee; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

Review 4.  Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?

Authors:  Andrew McLean-Tooke; Catherine Aldridge; Sheila Waugh; Gavin P Spickett; Lesley Kay
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580

Review 5.  Autochthonous hepatitis e virus infections: a new transfusion-associated risk?

Authors:  Jens Dreier; David Juhl
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

6.  Seroprevalence of hepatitis E virus in domestic pigs and wild boars in Switzerland.

Authors:  C Burri; F Vial; M-P Ryser-Degiorgis; H Schwermer; K Darling; M Reist; N Wu; O Beerli; J Schöning; M Cavassini; A Waldvogel
Journal:  Zoonoses Public Health       Date:  2014-02-06       Impact factor: 2.702

7.  Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E.

Authors:  M Fogeda; F de Ory; A Avellón; J M Echevarría
Journal:  J Clin Virol       Date:  2009-06-07       Impact factor: 3.168

8.  Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis.

Authors:  Nathalie Balandraud; Sandrine Guis; Jean Baptiste Meynard; Isabelle Auger; Jean Roudier; Chantal Roudier
Journal:  Arthritis Rheum       Date:  2007-06-15

Review 9.  Hepatitis E: an emerging awareness of an old disease.

Authors:  R H Purcell; S U Emerson
Journal:  J Hepatol       Date:  2008-01-02       Impact factor: 25.083

10.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

Authors:  Wen-hai Feng; Jeffrey I Cohen; Steven Fischer; Li Li; Michael Sneller; Raphael Goldbach-Mansky; Nancy Raab-Traub; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  1 in total

1.  Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review.

Authors:  Hidekazu Ikeuchi; Kana Koinuma; Masao Nakasatomi; Toru Sakairi; Yoriaki Kaneko; Akito Maeshima; Yuichi Yamazaki; Hiroaki Okamoto; Toshihide Mimura; Satoshi Mochida; Yoshihisa Nojima; Keiju Hiromura
Journal:  Case Rep Rheumatol       Date:  2018-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.